Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed supratentorial glioblastoma multiforme
• •Must have undergone a biopsy OR subtotal or gross total resection of the tumor
• •Must have completed post-operative (or post-biopsy) radiotherapy within the past 5 weeks
• •* No progressive disease after radiotherapy
• •PATIENT CHARACTERISTICS:
• •Age
• •18 and over
• •Performance status
• •Karnofsky 60-100%
• •Life expectancy
• •Not specified
• •Hematopoietic
• •Absolute neutrophil count ≥ 1,500/mm\^3
• •Platelet count ≥ 100,000/mm\^3
• •Hepatic
• •Serum glutamate pyruvate transaminase (SGPT) \< 2 times upper limit of normal (ULN)
• •Alkaline phosphatase \< 2 times ULN
• •Bilirubin ≤ 1.5 mg/dL
• •Renal
• •blood urea nitrogen (BUN) ≤ 1.5 times ULN
• •Creatinine ≤ 1.5 times ULN
• •Immunologic
• •No history of allergic reactions attributed to compounds of similar chemical or biological composition to celecoxib or to sulfonamides
• •No asthma, urticaria, or allergic reactions to aspirin or other NSAIDs
• •No active infection
• •Gastrointestinal
• •No inflammatory bowel disease
• •No history of peptic ulcer disease
• •No gastrointestinal bleeding within past 3 months
• •Other
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective double-method contraception during and for 2 months after study participation
• •* Fertile female patients randomized to receive thalidomide must use effective double-method contraception for ≥ 4 weeks before, during, and ≥ 4 weeks after completion of study therapy
• •* Fertile male patients randomized to receive thalidomide must use effective contraception during and for ≥ 4 weeks after completion of study therapy
• •No blood donation (for patients randomized to receive thalidomide)
• •No history of any other cancer except nonmelanoma skin cancer or carcinoma in situ of the cervix or cancer that is in complete remission and patient completed all therapy for that disease ≥ 3 years ago
• •No other disease that would obscure toxicity or dangerously alter drug metabolism (e.g., severe connective tissue disease)
• •No other serious medical illness
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •Not specified
• •Chemotherapy
• •Prior temozolomide in combination with radiotherapy allowed
• •No other prior or concurrent chemotherapy
• •Endocrine therapy
• •Not specified
• •Radiotherapy
• •See Disease Characteristics
• •See Chemotherapy
• •Surgery
• •See Disease Characteristics
• •No concurrent surgery
• •Other
• •No other concurrent non-steroidal anti-inflammatory drugs (NSAIDs) (for patients randomized to receive celecoxib)
• •No other concurrent investigational drugs
• •No other concurrent anticancer therapy